WASHINGTON, DC (May 20, 2026) – Sodium-glucose cotransporter-2 inhibitors (SGLT2is) may represent a promising strategy to mitigate anthracycline-induced cardiomyopathy in cancer patients, according to a review published in the May issue of Journal of Cardiac Failure-Intersections. The article highlights evidence linking SGLT2i therapy with reductions in new-onset heart failure, heart failure hospitalizations, and mortality among patients receiving anthracycline treatment, while also emphasizing the drugs’ favorable safety profile in cardio-oncology populations.
The May issue also brings together new research and clinical perspectives on frailty management in adults living with heart failure and complex treatment decision-making for patients with advanced functional mitral regurgitation.
Study Highlights Gaps and Opportunities in Frailty Management
Another study, Patient and Clinician Perspectives on a Multicomponent Frailty Intervention for Adults With Heart Failure: A Qualitative Study, examines how patients and clinicians believe frailty interventions should be structured to improve both feasibility and outcomes. Through focus groups involving adults living with heart failure and clinicians with expertise in heart failure and frailty, the study identified several priorities for future interventions, including personalized exercise programs, stronger integration of nutrition support and dietitians into heart failure care, and expanded psychosocial and social engagement resources. Participants also emphasized the importance of flexible and digital follow-up models to support long-term participation and adherence.
Advanced Functional Mitral Regurgitation: When Is Repair Enough?
The issue also includes a Teachable Moment article addressing one of the most difficult clinical questions in advanced heart failure management: when patients with severe functional mitral regurgitation should undergo transcatheter edge-to-edge repair versus referral for advanced therapies such as left ventricular assist device (LVAD) support. Using a detailed patient case involving severe ventricular dysfunction, persistent symptoms despite maximally tolerated guideline-directed medical therapy, worsening renal dysfunction, and severe functional mitral regurgitation, the article walks clinicians through the multidisciplinary considerations involved in determining the next therapeutic step.
View the full issue online. For interviews with authors, please contact Laura Poko at [email protected].
About the Journal of Cardiac Failure-Intersections
The Journal of Cardiac Failure-Intersections is an open-access journal with a focus on heart failure and its various intersections with other disciplines and specialties within the broader cardiovascular community. The journal has a special focus on how multidisciplinary partnerships impact patient care. Published papers will span original investigator-initiated work to state-of-the-art reviews, expert perspectives, including those with a global viewpoint, early career and trainee spotlight pieces, and patient and patient-partner narratives.
About the Heart Failure Society of America
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.
Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected]